| Literature DB >> 33552390 |
Maria Michela Chiarello1, Maria Cariati1, Giuseppe Brisinda2.
Abstract
The most common localization for intestinal Crohn's disease (CD) is the terminal ileum and ileocecal area. It is estimated that patients with CD have one in four chance of undergoing surgery during their life. As surgery in ulcerative colitis ultimately cures the disease, in CD, regardless of the extent of bowel removed, the risk of disease recurrence is as high as 40%. In elective surgery, management of isolated Crohn's colitis continues to evolve. Depending on the type of surgery performed, colonic CD patients often require further medical or surgical therapy to prevent or treat recurrence. The elective surgical treatment of colonic CD is strictly dependent on the localization of disease, and the choice of the procedure is dependent of the extent of colonic involvement and previous resection. The most common surgical options in colonic CD are total proctocolectomy (TPC) with permanent ileostomy, segmental bowel resection, subtotal colectomy. TPC completely removes all colonic and rectal disease and avoids the use of a potentially diseased anus. We will review current options for the elective surgical treatment of colonic CD, based on the current literature and our own personal experience. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Colonic Crohn’s disease; Colonic resection; Crohn’s disease; Segmental colectomy; Surgery; Surgical treatment; Total colectomy
Year: 2021 PMID: 33552390 PMCID: PMC7830073 DOI: 10.4240/wjgs.v13.i1.1
Source DB: PubMed Journal: World J Gastrointest Surg
Features of ileal/ileocolonic Crohn’s disease, isolated colonic Crohn’s disease, and ulcerative colitis
| Characteristics | Ileal and ileocolonic CD | Isolated colonic CD | Ulcerative colitis |
| Sex | Slight female predominance (55%) | Female predominance (65%) | Equal or slight male predominance |
| Genetics | Crohn’s-associated genotype including NOD2/CARD15 | Genotype midway between CD and UC | UC-associated genotype including HLA-DRB1*01:03 |
| Serology | ASCA commonly positive; pANCA usually negative | ASCA less commonly positive than ileal CD; pANCA positive | ASCA usually negative; pANCA commonly positive |
| Mucosa-associated microbiota | Marked changes commonly including increased proteobacteria ( | Intermediate changes similar to ileal/ileocolonic CD but less consistent | Modest changes, including slight increase in |
| Response to mesalazine | No efficacy | No efficacy | Good efficacy |
| Response to anti-TNF | Good efficacy | Good efficacy, probably better than for ileal/ileocolonic CD | Good efficacy |
| Response to exclusive enteral nutrition | Good efficacy | Probably good efficacy | No efficacy |
| Surgery rate and type | Required in majority | Required in minority. High failure for pouch-anal reconstruction | Required in minority. Low failure for pouch-anal reconstruction |
CD: Crohn’s disease; ASCA: Anti-Saccharomyces cerevisiae; HLA: Human leucocyte antigen; pANCA: Perinuclear antineutrophil cytoplasmic antibodies; TNF: Tumor necrosis factor; UC: Ulcerative colitis.
Figure 1Surgical procedures and indications in isolated colonic Crohn’s disease.
Recurrence after segmental bowel resection and after total colectomy in patients with isolated colonic Crohn’s disease
| Ref. | Patient/type of surgery | Recurrence rate (%) |
| Longo | 18 segmental bowel resection | 62 |
| 131 total colectomy | 65 | |
| Allan | 36 segmental bowel resection | 66 |
| 63 total colectomy | 53 | |
| Bernell | 134 segmental bowel resection | 49 |
| 106 total colectomy | 53 | |
| Andersson | 31 segmental bowel resection | 39 |
| 26 total colectomy | 46 | |
| Martel | 84 segmental bowel resection | 43 |
| 39 total colectomy | 41 | |
| Fichera | 55 segmental bowel resection | 38.8 |
| 49 total colectomy | 22.9 | |
| 75 total proctocolectomy | 9.3 |